Alternatives to Retacrit If You Can't Fill Your Prescription

Running out of Retacrit (epoetin alfa-epbx) is a serious concern for patients who depend on it to manage anemia from chronic kidney disease, chemotherapy, or HIV treatment. The good news: there are legitimate, FDA-approved alternatives. The critical point: you should never switch ESAs without your doctor's guidance. Here's what you need to know.

Important: Never Stop Retacrit Without Talking to Your Doctor

Retacrit is a life-sustaining medication for many patients. Stopping it abruptly can allow hemoglobin levels to fall sharply, potentially requiring blood transfusions or emergency care. If you can't find Retacrit in stock, call your prescriber's office immediately — do not simply skip doses while you search.

Alternative #1: Epogen (Epoetin Alfa) — Amgen

Epogen is one of the two original brand-name reference products for which Retacrit is a biosimilar. It contains the same active ingredient — epoetin alfa — and is FDA-approved for the exact same indications:

• Anemia due to chronic kidney disease (dialysis and non-dialysis)
• Anemia from zidovudine in HIV patients
• Anemia due to myelosuppressive chemotherapy
• Reduction of transfusions in elective, noncardiac, nonvascular surgery

Epogen is widely used in dialysis centers. Because it is NOT designated as interchangeable with Retacrit, your prescriber must write a new prescription specifically for Epogen. It is generally more expensive than Retacrit as the brand-name originator product.

Alternative #2: Procrit (Epoetin Alfa) — Janssen

Procrit is the other original brand-name reference product. Like Epogen, it contains epoetin alfa and shares all FDA-approved indications with Retacrit. Procrit has traditionally been used more in oncology and non-dialysis settings, while Epogen dominates in dialysis.

One key clinical note: unlike Procrit, Retacrit does not contain human albumin as an excipient. This is rarely clinically significant, but it's worth mentioning to your prescriber if you have any albumin sensitivity.

Like Epogen, a new Procrit prescription from your doctor is required. Prior authorization from your insurer may also be needed if Retacrit is your plan's preferred ESA.

Alternative #3: Aranesp (Darbepoetin Alfa) — Amgen

Aranesp (darbepoetin alfa) is a longer-acting ESA. While Retacrit is typically dosed 3 times per week (or weekly in some chemotherapy protocols), Aranesp is dosed once every 1–3 weeks for CKD patients and once weekly or every 3 weeks for chemotherapy patients.

Aranesp is FDA-approved for:

• Anemia due to CKD (dialysis and non-dialysis patients)
• Anemia due to myelosuppressive chemotherapy in cancer patients

Note that Aranesp is NOT approved for HIV-related anemia or surgical anemia reduction — so it may not be suitable for every Retacrit patient. Dose conversion is also required, as darbepoetin alfa is a different molecule than epoetin alfa. Your nephrologist or oncologist will calculate the appropriate equivalent dose.

Alternative #4: Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)

Mircera is a continuous erythropoietin receptor activator (CERA) used for CKD-related anemia. It is dosed only once every 2 weeks or once monthly, making it the least frequent of all ESA options. However, it is only approved for CKD anemia — not for chemotherapy or HIV-related anemia.

Mircera may be a good option for stable CKD patients who are inconvenienced by frequent injections or who prefer monthly dosing.

Comparison Table: ESA Alternatives to Retacrit

Epogen (epoetin alfa): Same molecule as Retacrit. Approved for CKD, HIV, chemo anemia, and surgery. Dosed 3x/week. Higher cost than Retacrit.

Procrit (epoetin alfa): Same molecule as Retacrit. Approved for CKD, HIV, chemo anemia, and surgery. Dosed 3x/week. Higher cost than Retacrit.

Aranesp (darbepoetin alfa): Different molecule, longer half-life. Approved for CKD and chemo anemia (NOT HIV or surgery). Dosed weekly to every 3 weeks. Dose conversion required.

Mircera (methoxy PEG-epoetin beta): Different molecule, very long half-life. Approved for CKD anemia ONLY. Dosed every 2 weeks to monthly. Dose conversion required.

How to Ask Your Doctor About Switching

When you call your prescriber's office, be prepared with:

• Your current Retacrit dose and vial strength
• Your most recent hemoglobin/hematocrit lab results
• Your insurance plan's preferred ESA list (if you know it)
• How many doses you have remaining before you run out

Your doctor will need to issue a new prescription for whichever alternative you use and may need to submit a new prior authorization to your insurance. Acting early — before you run out — gives everyone more time to sort through these steps.

The Bottom Line

If you can't find Retacrit, you're not without options — Epogen, Procrit, Aranesp, and Mircera all offer similar clinical benefits for various anemia types. But the switch must be medically supervised. Contact your prescriber as soon as you know Retacrit is unavailable, use tools like medfinder to check if any pharmacy nearby has your specific Retacrit strength in stock, and read our guide on why Retacrit is hard to find for additional context.